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Abstract 38 
Lifetime risk of developing colorectal cancer is 5% and five-year survival at early-stage is 39 
92%.  Individuals with pre-cancerous lesions removed at primary screening are typically 40 
recommended surveillance colonoscopy.  Since greater benefits are anticipated for those 41 
with higher risk of colorectal cancer, scope for risk-specific surveillance recommendations 42 
exists.  This review assesses published cost-effectiveness estimates of post-polypectomy 43 
surveillance to consider the potential for personalised recommendations by risk-group.  44 
Meta-analyses of incidence of advanced-neoplasia post-polypectomy for low-risk cases were 45 
comparable to those without adenoma; with both rates under the lifetime risk of 5%.  This 46 
group may not benefit from intensive surveillance, which risks unnecessary harms and 47 
inefficient use of often scarce colonoscopy capacity.  Therefore, greater personalisation 48 
through de-intensified strategies for low-risk individuals could be beneficial.  The potential 49 
for non-invasive testing such as faecal immunochemical tests combined with primary 50 
prevention or chemoprevention may reserve colonoscopy for targeted use in personalised 51 
risk-stratified surveillance.   52 
 53 
This review appraised evidence supporting a program of personalised surveillance in 54 
patients with colorectal adenoma according to risk-group and compared the effectiveness of 55 
surveillance colonoscopy with alternative prevention strategies.  It assessed trade-offs 56 
between costs, benefits and adverse effects which must be considered in a decision to 57 
adopt or reject personalised surveillance.  58 
Key Words: 59 
Colorectal cancer, adenoma, cost-effectiveness, Precision Medicine, early detection, cancer 60 
prevention, surveillance 61 
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Background 62 
Lifetime risk of developing colorectal cancer (CRC) is 5% for an average risk individual in the 63 
US1.  CRC is the third most common cancer globally and imposes a significant burden of ill-64 
health2 .  Worldwide, CRC deaths form 8.5% of total cancer deaths (694,000 annually)3.  65 
Many deaths could be avoided by early detection through screening4,5; as given five-year 66 
relative survival rates for CRC detected at a local stage are 92%6.   67 
 68 
Screening programs have been widely implemented to manage CRC risk7.  Such programs 69 
employ colonoscopy either as the primary test or as a diagnostic test following a positive 70 
finding on a non-invasive stool test, which detects blood or other markers suggestive of 71 
cancerous lesions.  Colonoscopy offers direct visualisation and examination of the entire 72 
colon permitting the identification and removal of polyps leading, it is thought, to the 73 
prevention of CRC5.   74 
 75 
There are concerns over claims that screening programs reduce mortality or improve 76 
survival8, based largely on arguments related to lead time bias.  Lead time bias occurs when 77 
a diagnostic test merely identifies the disease earlier, thus increasing perceived survival 78 
without significant modification of the disease course9.  Despite such concerns, a recent 79 
meta-analysis of randomised screening trials (which addressed the effect of lead-time bias,) 80 
showed that one CRC death is prevented for every 1000 people screened, with this benefit 81 
being manifest on average after 9.4 years9,10.   Moreover, micro-simulation modeling is 82 
reported to show that declines in CRC death rates are consistent with a relatively large 83 
contribution from screening11.  While there is considerable randomised control trial 84 
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evidence to support screening overall, the magnitude of benefit available for surveillance (in 85 
terms of CRC deaths prevented) is uncertain.   86 
 87 
Post-polypectomy surveillance by colonoscopy has become a common feature of CRC 88 
prevention strategies12,13, offering intensive monitoring to individuals with prior 89 
precancerous findings at primary screening14.  In the case of colorectal screening, 90 
appropriate surveillance after endoscopic diagnosis of an adenoma15, is typically a strategy 91 
of surveillance colonoscopy at intervals of between 3 and 10 years.  Surveillance intensity 92 
can be adjusted dependent on an individual’s estimated CRC risk, as predicted by the 93 
number and grade of polyps removed at index colonoscopy.  Despite being widely 94 
recommended, the evidence that post-polyp surveillance reduces CRC incidence or 95 
mortality is lacking and is rarely established for sub-groups16.   96 
 97 
Up to 85% of CRCs are thought to develop from conventional adenomas17.  Adenomas begin 98 
in the glandular tissue lining the colon and while many are benign, some may have 99 
malignant potential.  Genetic changes in the colon’s lining can lead to malignancy as a result 100 
of a complex multi-step process in which adenoma is an intermediate stage.  A process 101 
referred to as the adenoma-to-carcinoma sequence, taking an estimated 7 to 15 years17–20.  102 
The long preclinical sojourn time of many adenomas creates the opportunity for successful 103 
early detection through screening.  Reported adenoma prevalence is estimated at 20-53% in 104 
persons over 50 years, with gender differences showing higher prevalence (40%) in men 105 
than in women (29%)17,21.   106 
 107 
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 Colonic polyps were conventionally classified as either hyperplastic or adenomatous, of 108 
which the latter were believed to have the potential to progress to carcinoma22.  Advances 109 
in genetic pathology are alleviating so called ‘variant classification’ which ‘obfuscated the 110 
correct classification’ of sessile serrated adenomas23, which unfortunately, were not as 111 
readily detected by many screening tests.  As new information emerges it is possible that 112 
sessile serrated lesions may be responsible for up to 30% of CRC.  The implications of the 113 
different pathologies for clinical management warrant the vigilance of physicians who may 114 
consider follow-up colonoscopies in accordance with sessile serrated adenomas 115 
guidelines24–27.  Although sessile lesions may have greater contribution to CRC than 116 
previously thought, this review focuses on the evidence related to adenomatous polyp risk 117 
groups. 118 
 119 
Although there is limited decisive evidence from colon-polyp surveillance, current guidelines 120 
for post-polypectomy surveillance employ explicit risk stratification by sub-groups, using the 121 
predictive features of adenomas detected at screening colonoscopy28.  The size, the number 122 
of polyps and their histology provide further qualification in differentiating those with 123 
tubular features from those with villous features, considered more likely to have cancers 124 
develop in them29.  For example, US guidelines recommend that individuals with 3–10 125 
adenomas undergo a surveillance colonoscopy every 3 years, while those with 1–2 tubular 126 
adenomas <10mm receive a surveillance colonoscopy every 5-10 years30.  Surveillance 127 
colonoscopies account for approximately 25% of colonoscopies among people over 50 years 128 
in the US31.   129 
 130 
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 While the surveillance guidelines are clear, conflicting reporting might lead to a conclusion 131 
that these persons are at a significantly increased risk, whilst other reports contend that 132 
many of the lesions detected at screening are likely to be of low risk.  It has been suggested 133 
that following initial detection and removal of adenomas, approximately half of people 134 
(51.4%) will have further adenomas within 3 years of initial colonoscopy, of which significant 135 
numbers may meet at least one criterion for advanced adenoma13,32–35.  However, 84% of all 136 
polyps removed at colonoscopy in a large screening study of 13,992 participants were less 137 
than 10mm.  Within a subset of the study population, CRC was detected in 0.03% of 138 
participants whose largest polyp was 1-5mm, (1 patient amongst 3744 patients with polyps 139 
1-5mm), moreover only 3 of the 74 cancers detected were found as a consequence of 140 
detecting advanced adenomas17,36.  Consequently, screening typically generates many 141 
‘positive’ findings that ultimately may be of low-risk, accounting for a small portion of 142 
cancer cases, meaning that large numbers of patients will be referred to surveillance, the 143 
clinical utility of which can be debated17,36.   144 
 145 
Whilst one benefit of surveillance is the possibility to detect lesions of significance, it may 146 
expose patients to unnecessary risks as a result of overdiagnosis, that is, the inclusion of 147 
‘pseudodisease,’ that would not become evident before the patient dies of other causes37.  148 
For example, it was reported that CRC was diagnosed in 19 of 2915 patients, who were 149 
deemed free of remaining lesions at a baseline clearing colonoscopy, over a mean follow-up 150 
of 3.7 years (incidence, 1.74 cancers/ 1000 person-years) amongst those in close 151 
surveillance.  Equating to 0.65% of atypical post-polypectomy surveillance participants 152 
developing CRC38, this includes a considerable numbers of individuals who undergo a 153 
surveillance test who could therefore be considered subject to over-diagnosis.   154 
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 155 
Some regions are adopting resect and discard policies, whereby lesions judged by the 156 
clinician performing polypectomy not to be of high risk can be discarded without being 157 
evaluated by a pathologist, thus reducing the risk of procedural over diagnosis39.  Another 158 
obvious means to lower potential overdiagnosis and limit the harms of invasive testing 159 
might be to consider an alternative to colonoscopy and to personalise approaches to 160 
surveillance by exploring the role of faecal immunochemical testing (FIT)40.  In a recent 161 
systematic review, FIT shows high diagnostic accuracy for detecting CRC and has shown the 162 
capability of quantifying and adjusting cut-off concentrations for positivity41–43.  Moreover, 163 
its acceptability to patients has also been demonstrated44.  Therefore, FIT could be an 164 
appropriate, acceptable and cost-effective surveillance test.   165 
  166 
Decision making requires careful balancing to avoid either too little surveillance, which may 167 
jeopardise CRC prevention goals, or lead to overuse of surveillance, chancing unnecessary 168 
harms and inefficient use of colonoscopy resources45.  Health economic evaluations aim to 169 
impartially identify, measure and compare the cost and consequences of the different 170 
interventions being considered to manage particular clinical problems46.  Recent economic 171 
evaluation in the US estimated an inflection point between conferring benefit and risking 172 
harm in the use of colonoscopy in older adults47,48, whereby the anticipated harms of false 173 
positives and unnecessary investigations outweighed the benefits of early detection.   174 
 175 
The relevant resource utilisation relates not only to the financial costs of providing 176 
surveillance, but also to colonoscopy capacity, which is often constrained in many health 177 
systems.  Therefore, decision makers need to consider how best to allocate the limited 178 
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number of colonoscopy examinations to those individuals with the greatest likelihood of 179 
benefit. 180 
 181 
Consensus has not yet emerged on what personalised surveillance practice ought to involve, 182 
with variation in current guideline recommendations shown in Table 1.  For example, Japan 183 
does not differentiate its surveillance guidance by risk category; recommending 184 
colonoscopy every three years, whereas the UK recommendations vary between annual 185 
colonoscopy for high-risk patients and five year colonoscopy (or return to screening) for 186 
low-risk patients.  Concerns over how best to balance surveillance intensity will be 187 
increasingly pressing given anticipated growth in numbers of people being directed into 188 
surveillance colonoscopy14, in part due to demographic aging and changes in the primary 189 
screening technology employed. 190 
 191 
Current data suggest that screening colonoscopy may identify patients at low risk of death 192 
from colorectal cancer or who may derive greatest value from a single screening test, but 193 
who may not benefit from subsequent intensive surveillance49,50.  Although meta-analysis of 194 
incidence of advanced neoplasia after polypectomy for a low-risk individual is comparable to 195 
persons without findings of an adenoma at colonoscopy, absolute risk in both groups was 196 
under the average persons’ lifetime risk of 5% (low-risk 3.6% vs without adenoma 1.6%)51.  197 
This indicates that the low-risk group may indeed have a CRC risk that is broadly comparable 198 
to the average risk population eligible for primary screening.  For that reason, there may be 199 
arguments for de-intensifying surveillance towards the types of screening frequencies and 200 
non-invasive testing technologies used in primary screening, which in turn would lead to 201 
greater personalisation of colonoscopy use.     202 
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 203 
Existing approaches to the adjustment of surveillance intensity rely on the frequency of 204 
testing, that is, through changes to the interval of use of the current technology 205 
(colonoscopy), offering, for example, 3 and 5-10 year colonoscopy30.  The ability to vary 206 
surveillance has been limited to this interval approach.  Newer, more effective stool tests 207 
may offer the ability to change the type of test offered, which may add flexibility to 208 
surveillance programs and as a result reduce the number of colonoscopies required during 209 
surveillance.   210 
 211 
Accordingly, this systematic review has three aims: 212 
1. To assess if there is sufficient evidence to evaluate a program of personalised 213 
surveillance in patients with colorectal adenoma according to risk sub-group. 214 
2. To compare the effectiveness of surveillance colonoscopy with alternative 215 
prevention strategies. 216 
3. To assess trade-off between costs (resource use), benefits and adverse effects 217 
that need to be considered in a decision to adopt or reject personalised 218 
surveillance. 219 
 220 
Methods  221 
Data Sources and Search Strategy  222 
The systematic review was conducted according to the Preferred Reporting Items for 223 
Systematic Reviews and Meta-analyses (PRISMA) guidance recommendations52,53 and the 224 
Centre for Reviews and Dissemination guidance46.  The review has been registered with 225 
PROSPERO – reference: CRD42016033509.   226 
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 227 
An initial check for previous reviews on the topic was conducted, as recommended46,54.  The 228 
search for the key words ‘adenoma’ AND ‘cost’ in ANY FIELD (September 2015), was carried 229 
out within the Centre for Reviews and Dissemination database including all databases 230 
(DARE, NHS EED and HTA; those most specific to economic evaluations of health and social 231 
care interventions)55.  This search indicated no existing systematic reviews addressing cost-232 
effectiveness within colorectal adenoma surveillance and prevention programs. 233 
 234 
The systematic review search strategy was optimised with help from a Specialist Medical 235 
Librarian (RF), informing the choice of available databases and developing the search to 236 
meet the needs of the review.  The search strategy was run in MEDLINE, MEDLINE in-237 
process and EMBASE.  These databases were searched from their inception to February 238 
2016, for key words, medical subject heading terms and synonyms of:  239 
 (a) Colorectal neoplasms OR adenoma.   240 
(b) Costs-benefit analysis OR synonyms. 241 
(c) Early detection of cancer OR surveillance. 242 
Searches a, b and c were then combined with AND, as shown in Web Appendix 1.   243 
 244 
In order to optimise the resultant yield of studies, we expanded the medical subject heading 245 
terms, used a modified strategy in each database (MEDLINE / EMBASE) to identify the 246 
literature under relevant terms and included techniques for word proximity and suffixes, 247 
which optimised database search tools to find relevant papers.   248 
 249 
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The titles and abstracts of the studies returned by the database searches were then 250 
screened for inclusion by eligibility criteria according to the patient population or the 251 
disease being addressed (P) the interventions or exposure (I) the comparator group (C) the 252 
outcome or endpoint (O) the study date / time frame (T) and the study design chosen (S) – 253 
‘PICOTS’ criteria56, as shown in Table 2.  The reference lists of the retrieved studies were 254 
searched to find studies not captured by our database searches.   255 
 256 
Study selection was conducted in three stages, as shown in Figure 1, including removal of 257 
duplicates (n=264), title and abstract screening against the PICOTS criteria (n=1009) and 258 
independent screening of all full text articles (n= 32) to confirm their eligibility, by two 259 
reviewers (EMF / JFOM); conducted according to the selection criteria detailed in Web 260 
Appendix 2.  In order to minimize bias, studies were retained in situations where both 261 
reviewers were not in agreement on exclusion, with discrepancies resolved by adjudication 262 
with a third reviewer.  All excluded papers were codified by ineligibility of PICOTS category.  263 
This process resulted in n=7 papers that were fully evaluated for the review. 264 
 265 
Data Extraction and Identification of Cost-Effectiveness Analyses 266 
We extracted the initial data from each study using the Consolidated Health Economic 267 
Evaluation Reporting Standards statement checklist tool57.  We have not conducted a meta-268 
analysis as the outcomes of economic evaluations are typically not commensurate for 269 
comparison.  Some studies reported incremental cost-effectiveness ratios (ICERs) that differ 270 
from the conventional interpretation, as the ratio of incremental costs to incremental health 271 
effects, relative to the next most effective strategy58, whereby strategies that are more 272 
costly and less effective are ruled out by simple or extended dominance59,60.  In these 273 
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instances, the ICERs were recalculated from the reported costs and effects and replicated 274 
cost-effectiveness estimations were used to re-examine the comparisons and analyses made 275 
by the studies, as carried out in another recent review61.  The recalculated results are 276 
presented alongside the originally published results in Web Table 1. 277 
 278 
Results 279 
Study Descriptions 280 
The systematic review returned 7 papers that were fully evaluated.  An overview of the key 281 
quality attributes of each paper as assessed in this review is given in Web Table 2, following 282 
the Consolidated Health Economic Evaluation Reporting Standards quality indicators48,50,52–283 
57.  The studies were published between 1991 and 2011; no studies from more recent years 284 
were identified.   285 
 286 
In brief, the search returned a small number of studies and the prevention strategies 287 
compared in the studies varied such that not all compared the same alternative 288 
interventions.  Thus, the potential for cross-comparison of the effectiveness and cost-289 
effectiveness of particular strategies was limited.  Whilst some papers compare surveillance 290 
by colonoscopy to natural history, others model compared surveillance by colonoscopy to a 291 
screening colonoscopy a 10 year interval62, or for performing an early 1 year colonoscopy63, 292 
whilst other models compared surveillance colonoscopy combined with chemo-293 
prevention64,66and chemo-prevention alone compared to natural history65.   294 
 295 
Strategies considered include: 296 
•  one year surveillance by colonoscopy63,  297 
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• a three-year high-risk and five-year low-risk colonoscopy62,  298 
• a three-year high-risk and ten-year low-risk colonoscopy62,  299 
• a three-year high-risk  and three-year low-risk colonoscopy62, 300 
• aspirin as chemoprevention alone66, 301 
• aspirin therapy combined with colonscopy66, 302 
• celecoxib as chemoprevention alone65, 303 
• a three-year high-risk  colonoscopy 65, 304 
• calcium as chemoprevention alone64, 305 
• calcium therapy combined with colonoscopy64, 306 
• fixed interval / modified interval colonoscopy surveillance67.   307 
To address the primary aims of the review in a systematic way, the following sections 308 
critically address how respective papers’ methods, assumptions and outputs support or 309 
prohibit clear evidence for each objective. 310 
        311 
Evidence to support personalised surveillance by sub-group at index colonoscopy  312 
No papers reported cost-effectiveness results disaggregated by high-risk/ low-risk sub-313 
groups.  While two studies described clear elements of stratification, identifying high-risk 314 
and low-risk subgroups of patients with adenoma, neither reported a comparison of 315 
outcomes by these subgroups; rather they reported results as combined group data59,64.  316 
Accordingly, this limited what our review was able to determine regarding risk-optimised 317 
surveillance strategies.   318 
 319 
The reporting in one paper did permit a step wise comparison of interval change for 320 
surveillance by colonoscopy in high-risk and low-risk groups62.  The ICERs presented 321 
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indicated that it is beneficial to change from a 10 year interval colonoscopy to a 3 year 322 
interval for high-risk individuals62, as this strategy was more effective and its ICER of 323 
$5743/QALY indicated that it is a cost-effective policy change, within conventional 324 
thresholds thought to be at least $50,000/QALY68.  Whilst it is also beneficial to move from 325 
10 year interval colonoscopy to 5 year in low-risk individuals, the ICER of $296,266/QALY is 326 
greater than conventionally accepted thresholds for the US68.  Importantly, these results 327 
also indicated that more intensive surveillance by a change from a 5 year to 3 year interval 328 
for low-risk individuals resulted in reduced quality adjusted life years, (-0.0023 QALYs). This 329 
‘disutility of colonoscopy’, shows that it becomes more harmful for low-risk individuals to 330 
receive a more intensive surveillance strategy of a 3 year colonoscopy62. 331 
 332 
Effectiveness of colonoscopy compared to alternative prevention strategies 333 
An important purpose of this review was to find studies that compared alternatives to 334 
colonoscopy-based surveillance.  The review found no studies that considered other clinical 335 
test strategies in post-polypectomy surveillance other than colonoscopy.  All papers 336 
retrieved assumed that the default test for surveillance was colonoscopy.  There are, 337 
however, comparisons of colonoscopy to three types of chemoprevention drugs, all of 338 
which compared chemoprevention benefit to no intervention,64–66 or compared 339 
colonoscopy combined with chemoprevention to no intervention64,66.  A summary of the 340 
results from the strategies evaluated for surveillance is shown in Web Table 1. 341 
 342 
In addressing clinical variations in colonoscopy capacity, the most recent paper authored by 343 
Wilschut and colleages,59 used micro-simulation modelling with the MISCAN-Colon model 344 
(one of 3 internationally validated models which evaluate screening programs).  This 345 
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included 48 variations of the background screening program within which 2 surveillance 346 
strategies were simulated.  Although this study presented results for variation in the primary 347 
screening strategy, the reported results do not permit comparison of the two surveillance 348 
strategies considered.  The analysis considered whether it would be appropriate to offer 349 
colonoscopy surveillance under increasingly tight colonoscopy capacity constraints.  They 350 
found that an affordable ICER was achievable for colonoscopy surveillance when capacity 351 
was greater than 20 colonoscopies per 1,000 individuals59.  However, if the capacity of 352 
colonoscopy was <5 per 1,000 individuals offering low-risk groups surveillance colonoscopy 353 
was no longer considered an effective allocation of a scarce health resource59.   354 
 355 
Wilschut et al.’s analysis adds a modelling feature, not commonly employed in the other 356 
papers, that permits the simulation of the impact of both primary screening and subsequent 357 
surveillance59.  Moreover, it has the ability to evaluate issues of service capacity, alternate 358 
types of testing and a mix of tests which more accurately reflects the complexity of choice 359 
facing decision makers.  By comparison, the models used in other studies reviewed only 360 
characterise limited aspects of the decision problem. 361 
 362 
Hassan et al estimated the benefit of early annual colonoscopy compared with not doing an 363 
early annual colonoscopy, since their descriptions are not clear we clarify that they compare 364 
providing a 1 year to a 3 year test63.  They report an ICER of $66,136 per life year gained 365 
(LYG) for a comparison of annual colonoscopy to no yearly test63 (where ‘no test’ is 366 
modelled as a 3 year test).  However, the paper did not report total costs or total effects for 367 
the strategies considered; consequently, it was difficult to assess this ICER or its basis.  The 368 
modelling conducted in this comparison is for persons aged 60 years on entry to the 369 
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surveillance program.  This comparison may have somewhat limited clinical relevance in its 370 
chosen setting, as the recommended age to start screening in the US is 50 years7.  The 371 
finding that an annual colonoscopy may be cost-effective relative to a three year 372 
colonoscopy is in keeping with the results of an application of the U.K. guidelines in the U.S.  373 
which suggested a subset of high risk patients may warrant a one-year clearing 374 
colonoscopy69.         375 
 376 
Chemoprevention  377 
Although none of the reviewed studies considered tests other than colonoscopy, a range of 378 
chemoprevention strategies were evaluated64–66, one of which demonstrated that a strategy 379 
employing aspirin combined with colonoscopy is cost-effective66.  Focusing on the absolute 380 
differences in benefit, this study estimated that compared with no intervention, 381 
colonoscopy surveillance accrued +0.0124 life years saved (LYS) whilst aspirin combined 382 
with colonoscopy surveillance provided +0.0138 LYS66.   383 
 384 
DuPont et al reported ICERs for aspirin alone, colonoscopy surveillance alone and a 385 
combined intervention of aspirin with colonoscopy surveillance, which showed an ICERs of 386 
$87,609/ LYS, $78,226/ LYS, $60,492/ LYS respectively66.  These ICERs however appear to 387 
have been calculated differently from the conventional interpretation58.  As such, the 388 
reported ICER in the paper effectively becomes an average cost-effect, that is, the ratio of 389 
the cost to benefit of an intervention without reference to a comparator70.  Accordingly, we 390 
recalculated the ICERs from the reported costs and effects and the replicated cost-391 
effectiveness estimations plotted on a cost-effectiveness plane.  These re-estimated ICERs 392 
are reported in Web Table 1 alongside the reported figures from the paper.  This 393 
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reinterpretation of the results indicates that aspirin chemoprevention alone was subject to 394 
extended dominance, as was colonoscopy surveillance alone, meaning that they are not 395 
preferred from the cost-effectiveness perspective.  The combination of 3/5yr colonoscopy 396 
combined with aspirin had an ICER of $73,927/ LYS and as such remains a cost-effective 397 
strategy for the US.  This result shows that combination therapy is more cost-effective than 398 
either intervention alone, which is noteworthy and merits further investigation, given the 399 
role of aspirin in the prevention of premature mortality due to other causes.   400 
 401 
Arguedas and colleagues compared colonoscopy surveillance with no surveillance and 402 
demonstrated an incremental benefit of 0.01995 LYS (8.48482 life years vs 8.45487 life 403 
years), whilst celecoxib was estimated to provide a greater absolute gain in LYS, generating 404 
a further 0.00579 LYS relative to colonoscopy surveillance65.  Although celecoxib 405 
chemoprevention was estimated to be more effective than colonoscopy, the ICER of 406 
$1,715,199/ LYS was significantly above US thresholds68.    407 
 408 
Notably the DuPont et al, aspirin paper and the Arguedas paper evaluating 409 
chemoprevention using celecoxib, shared co-authors and employed similar models65,66.  410 
Whilst the DuPont et al title described addressing increased risk for CRC, the Arguedas et al 411 
paper described average-risk patients, however both models explained colonoscopy 412 
surveillance as colonoscopy ‘occurring 3 years after index colonoscopy’65,66.  Such 413 
description left it unclear if individuals eligible for a 5 year surveillance test were included.  414 
Whether these models in fact incorporated only those in the high-risk group, according to 415 
US guidelines30, was not fully supported by the parameter estimates for the models.  The 416 
cited reference for malignant transformation rate (0.1065) was taken from published data 417 
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for untreated polyps, rather than reported high-risk  transformation.  The probability 418 
reported differed in the aspirin analyses, where malignant transformation was reported as 419 
0.01, citing one shared reference, consequently in the absence of clear reporting, we cannot 420 
draw any firm conclusions about whether all those eligible for surveillance were modelled in 421 
either paper. 422 
 423 
The effectiveness of supplemental calcium as a chemoprevention was evaluated by Shaukat 424 
et al.  That analysis assessed a dose of 1.2g/day for age 50-80 years64,  not at the 3-4g/ day 425 
dose mentioned in the article as providing a reduction in adenoma recurrence of 22% 426 
compared to placebo in meta-analyses.  The article does not present a clear argument for 427 
using the lower dose selection.   428 
 429 
Like DuPont et al, Shaukat et al report an ICER for calcium chemoprevention alone however 430 
this strategy is subject to extended dominance and so would not be a preferred strategy and 431 
should not have an ICER reported for it64.  The recalculated ratios of costs and effects were 432 
replicated to provide cost-effectiveness estimations which were plotted on a cost-433 
effectiveness plane, reported in Web Table 1.  Based on the recalculated ratios the resultant 434 
ICER for surveillance colonoscopy was $20,494 /LYG when compared to natural history, with 435 
the combination of calcium chemoprevention and colonoscopy generating an ICER of 436 
$2,823,333 /LYG, based on the 0.0003 incremental LYG reported64, an ICER which is once 437 
again greater than US thresholds68.   438 
 439 
This reassessment of the reported results indicated that surveillance colonoscopy alone is 440 
cost-effective, whilst the ICERs indicated that the incremental cost, of additional health 441 
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benefits from chemoprevention by celecoxib alone or calcium combined with colonoscopy 442 
was likely to be very high, relative to the health gains.  It can tentatively be claimed that 443 
aspirin chemoprevention combined with surveillance colonoscopy appears to be cost-444 
effective, but given the ambiguity regarding risk-groups within the DuPont et al paper, the 445 
results merit further investigation to clarify if these are sub-group dependent or if they 446 
might apply to all adenoma patients.      447 
 448 
From the review we believe the salient points from the conclusions of these cost- 449 
effectiveness evaluations of colonoscopy based surveillance programs to be:  450 
(a) Colonoscopy capacity can, at lower levels, prohibit the ability of health systems to 451 
offer colonoscopy based surveillance to low-risk groups59. 452 
(b) Compared with a ten-year low-risk colonoscopy, offering a five-year colonoscopy to 453 
low-risk groups was above US thresholds at $296,266/ quality adjusted life year62. 454 
(c) Compared to a three-year high-risk colonoscopy, there is evidence to support 455 
offering a one-year high-risk* colonoscopy63 –  *for persons aged 60 years entering 456 
surveillance. 457 
(d) Aspirin combined with surveillance colonoscopy generated greater life years saved 458 
than aspirin or colonoscopy alone and in given its role in the prevention of 459 
premature mortality due to other causes, this combination merits further evaluation.   460 
There were quality and reporting issues with a number of the papers evaluated.  These 461 
shortcomings suggest that questions remain regarding the cost-effectiveness of post-462 
polypectomy surveillance programs.   463 
 464 
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The trade-off between costs (resource use) and beneficial or adverse effects that need to 465 
be considered in a decision to adopt or reject personalising surveillance 466 
Cost calculations of the strategies should account for all resources used.  Whilst all models 467 
included the costs of colonoscopy and polypectomy, program and administration costs were 468 
only described in two papers59,62.  Only one reviewed study attempted to address the 469 
treatment costs, accounting for newer therapies such as oxaliplatin, now recommended in 470 
advanced stage cancer, and terminal care costs 59,71,72.  Where these costs were estimated 471 
for the final year of life, there was some uncertainty as to how these were adjusted for 472 
according to heterogeneity by stage59.  There was no consistent approach to adjusting 473 
treatment costs according to the stage of disease62–64,72.  Adjustments for inflation were also 474 
unclear in some of the papers59,67.  Use of biologics, such as Cetuximab or Bevacizumab in 475 
treatment costs assumptions was not noted.     476 
 477 
Study costs were commonly taken from Medicare fee schedules for colonoscopy, 478 
polypectomy, complications and pathology62–66, or in some cases national reports62.  Only 479 
one study reported the type of distribution used for costs in probabilistic sensitivity 480 
analyses62.  Indirect costs, in the form of lost income to the patient and an escort, were 481 
included in only one study63.  Somewhat strangely, one study cited a long term arthritis trial 482 
for their $100,000 costs per CRC case, the provenance of which was uncertain given the 483 
source cited65.   484 
 485 
Resource costs for aspirin were given from a trial with wholesale prices used in sensitivity 486 
analyses66.  Calcium costs were described as constant over the period 2005-2008 prices64.  487 
There were some inconsistencies in referenced costs for ”incurable” CRC66, citing a base 488 
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case scenario ($40,000) with a maximum in the range ($100,000) from a source that used 489 
this maximum as its base case65.   490 
 491 
Health effects were calculated based on the estimated effect of colonoscopy and 492 
polypectomy and weighted by the risk of adenoma transformation in all models.  The use of 493 
a preference-weighted health state classification system such as the EuroQol-5D73 were not 494 
consistently reported.  No citations were presented for the utility estimates used in some 495 
models (for CRC at diagnosis and subsequently)59 while in others no measures for utility 496 
were given63. 497 
 498 
We noted a large difference in the modelled life expectancy (between 8.45487/ LYS65 and 499 
12.2847/LYS66) under no surveillance of celecoxib and aspirin from two studies that used 500 
related models in which the same discount rate was used and individuals were modelled 501 
from age 50 in both cases.  While the difference in life expectancy may relate to differences 502 
in risk subgroups between the analyses the difference still seems large, and was not readily 503 
explained65,66.  Whilst there is a 6 year gap in publishing, it is unclear whether this difference 504 
can be directly attributed to the characteristics modelled, surveillance program or to 505 
differences in the quality or practice of colonoscopy techniques over time24,74, or to 506 
treatment improvements72.   507 
 508 
It is inevitable that colonoscopy carries the risk of missed lesions, given as approximately 509 
22%  by meta- analyses75,76.  Missed polyps clearly have the potential to become interval 510 
cancers.  Only two of the studies reported a probability of a missed polyp; and there was a 511 
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noticeably large variation ranging from 0.08-0.2162,66 (where reported as a percentage, small 512 
adenoma=17.8% and large adenoma=4.6%64).  The remaining studies have not reported this 513 
within model parameters and it this implies it is not assessed within the analyses59,63,65.   514 
 515 
The risk of colonic perforation, as an adverse effect, was considered in all but one of the 516 
models63.  This was modelled with various probabilities; a base case probability of 0.000662, 517 
0.003 for colonoscopy alone65,66, or 0.02 with polypectomy65.  The origins of these rates are 518 
uncertain from the reported literature.  Although relatively rare, perforation can cause 519 
significant morbidity and even death (30 day morbidity rates of 21%-53% and mortality 520 
rates of 0%-26%, with hospital stay of up to 3 weeks77).   521 
 522 
Discussion  523 
The main policy-relevant issue emerging from this review was that no studies were found 524 
that evaluated the cost-effectiveness of colonoscopy against other tests, such as FIT or 525 
other non-invasive testing.  Colonoscopy has been the primary approach to post-526 
polypectomy surveillance since the early 1990s but it has not been compared with other 527 
tests in the surveillance of patients after polypectomy.  This is in spite of the availability of 528 
alternatives , such as FIT, which have been compared with colonoscopy in index screening 529 
evaluations78–82.   530 
 531 
Critically we acknowledge the gaps in cost-effectiveness reporting by sub-group. Since it is 532 
possible to implement different treatment decisions for patients with different 533 
characteristics, models should consider the potential for their results to vary across different 534 
subgroups to facilitate different policy decisions83.  As demand for testing changes over time 535 
24 
 
 
in screening programs, through the introduction of newer technologies and with trends in 536 
adherence and variable adenoma detection rate84, these issues require attention from 537 
policy makers and modellers to understand and explore the potential of modelling to 538 
provide a clear understanding of the risks and benefits in the choice of interventions 539 
adopted. 540 
   541 
Prior work has shown that FIT threshold for positivity can be adjusted within a screening 542 
program to optimise detection according to available colonoscopy capacity85, therefore post 543 
polypectomy surveillance could follow such an approach.  The role of FIT is being considered 544 
in surveillance with a trial in the UK currently comparing FIT vs colonoscopy86.  FIT offers 545 
improved performance over older stool-based testing techniques and its ability to adjust 546 
cut-off levels may allow for greater optimisation of resources given colonoscopy capacity 547 
constraints.   548 
 549 
The UK NHS Bowel Cancer Screening Programme recently recommended the primary test 550 
used be changed from guaiac-based faecal occult blood testing (gFOBT) to FIT87–89.  Such a 551 
change in the primary test used will likely affect the numbers of patients detected with 552 
advanced adenoma, and with it those eligible for surveillance90.  As part of this change there 553 
are planned adjustments to the FIT positivity cut-off value used, in order to continue to 554 
optimise the effectiveness of the planned technology in line with capacity changes and 555 
service transition.  These recommendations have acknowledged the likely systemic effect on 556 
colonoscopy capacity; as such it would seem pragmatic to consider not only the adjustment 557 
of FIT cut-off for screening but also its role within the surveillance context.  Whether 558 
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surveillance guidelines might be developed or modified to account for colonoscopy capacity 559 
is one issue that might be explored in future modelling studies. 560 
 561 
FIT has the potential to be an effective post-polypectomy surveillance test for suitable risk-562 
groups.  Reported uses in screening other high-risk groups (e.g.  first-degree relatives of 563 
patients with CRC) has revealed that annual FIT screening (over 3 years) detected all CRCs 564 
and proved equivalent to colonoscopy in detecting advanced neoplasia91.  FIT, when used 565 
between scheduled surveillance colonoscopies, has been shown to have detected neoplasia 566 
sooner than scheduled surveillances92.  Interval FIT analyses could be effectively used to 567 
detect missed or rapidly developing lesions in surveillance programs92.  FIT has a useful 568 
diagnostic role and it has also been suggested that FIT has a predictive capacity, with 569 
interval cancers independently predicted by faecal haemoglobin concentration (FHbC), 570 
which may be applied for tailored case management and modification based on FHbC93.   571 
 572 
The use of existing tests such as FIT, in innovative and adaptive ways, might help accrue 573 
benefits in more risk appropriate, prescribed and personalised surveillance-based 574 
approaches.  Addressing and personalising other known features of risk of CRC, such as diet 575 
and lifestyle, might offer increased precision and optimise the prevention of CRC.  Offering 576 
personalised surveillance with diet and lifestyle evaluation as a companion to non-invasive 577 
testing alternatives might support adopting a primary care rather than secondary care 578 
service design for prevention interventions to address the risk of colorectal cancer94,95.   579 
 580 
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In future, there may be more scope for increased personalisation of surveillance programs.  581 
Novel blood based tests such as predictive micro-RNAs, or combined biomarkers (β-catenin 582 
nuclear localisation, Cox-2 expression and p53 nuclear expression, were significantly 583 
associated with adenoma recurrence after 3 years (ß-catenin: p=0.002; Cox-2: p=0.001; p53: 584 
p=0.001).  These tests put forward predictions of adenoma recurrence with high negative 585 
predictive value (88.5%) and sensitivity (94.6%),  which if validated, would be equivalent to 586 
or better than current clinical risk stratification approaches based on adenoma size and 587 
frequeny28,32.      588 
 589 
Clinical Issues 590 
The most clinically-relevant issue raised by this review is that of the role of aspirin 591 
chemoprevention, recently endorsed by the updated US Preventative Task Force 592 
Recommendations96  and described as the first pharmacological agent to be endorsed for 593 
cancer chemoprevention97.  We have highlighted that aspirin combined with colonoscopy 594 
surveillance results in a reported ICER of $60, 942 (recalculated to be $73,927/ LYG), in what 595 
we might reasonably infer to be high-risk groups and might be considered a strategy for 596 
personalised surveillance.  Since some methodological issues were raised in the model 597 
reviewed within this paper, we believe it is highly relevant to consider an updated model 598 
which addresses the role of aspirin, taking cognisance of the known likelihood of a future 599 
precision medicine approach that is based on aspirin’s mechanism of action.   600 
 601 
The other key clinical issue highlighted in the review, was how readily results may be 602 
affected by differences in capacity of colonoscopy services or may be influenced by other 603 
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quality assurance issues such as adenoma detection rates.  As shown in other evaluations of 604 
screening, the adenoma detection rate was recognised as influencing the cost-effectiveness 605 
of screening programmes84.  There are recognised differences in this rate between 606 
screening and surveillance, which was significantly higher in surveillance colonoscopies 607 
(37%), compared with screening colonoscopies (25%; P < .001)24.  Future work 608 
acknowledging the impact of examination quality as characterised by adenoma detection 609 
rates, within decision models or colonoscopy capacity planning would allow robust 610 
evaluation of the benefits of surveillance.  In so doing, we can more fully evaluate if 611 
infrequent high-quality colonoscopy exams are indeed more effective in preventing CRC 612 
than are frequent low-quality colonoscopy exams35.   613 
 614 
Limitations  615 
Potential limitations of the review are that as a result of our search strategy we do not 616 
characterise the grey literature related to the economic evaluation of surveillance in 617 
colorectal adenoma post-polypectomy surveillance. 618 
 619 
Conclusion  620 
We suggest a cautious interpretation of the findings of cost-effectiveness of colonoscopy-621 
based post-polypectomy surveillance due to the small number of studies addressing the 622 
topic.  Based on the reviewed literature we would suggest that future investigations update 623 
and confirm the benefits reported, in particular exploring comparisons of the cost-624 
effectiveness of newer testing alternatives, such as FIT or newer tests like micro-RNA.  In 625 
particular, we suggest examination of where FIT may provide clinically accessible 626 
adjustments to cut-off levels, and triage national or regional resources optimally based on 627 
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national or regional quality indicators and capacity.  The insights on cost-effectiveness of 628 
combined aspirin and colonoscopy merit further exploration in light of the updated 629 
literature on the role of aspirin in chemoprevention and its likely role the in prevention of 630 
premature mortality due to other causes.  Taken together, these results suggest that there 631 
are valuable alternatives to current guidelines which should be explored in updated cost-632 
effectiveness models. 633 
634 
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Tables 635 
Table 1  –Guidelines for surveillance following polypectomy  636 
Location Year Surveillance Recommendations Interval Reference 
No. 
UK / New 
Zealand 
2011 Low Risk - one or two adenomas smaller than 
10 mm. 
Consider colonoscopy at 5 
years or return to screening (by 
gFOBT) 
98,99 
Intermediate Risk - three or four adenomas 
smaller than 10 mm or one or two adenomas if 
one is 10 mm or larger. 
3 year colonoscopy  
High-risk - five or more adenomas smaller than 
10 mm or three or more adenomas if one is 10 
mm or larger. 
1 year colonoscopy  
US 2012 No polyps / distal small 
(<10 mm) hyperplastic polyps. 
10 year colonoscopy  30 
1–2 tubular adenomas <10mm  5 -10 year colonoscopy  
3–10 adenomas 3 year colonoscopy 
>10 adenomas <3 year colonoscopy (states - 
‘no basis for less than 3 years,’ 
< symbol as shown in paper). 
one or more tubular adenomas >10 mm / one 
or more villous adenomas / adenoma with high 
grade dysplasia  
3 year colonoscopy 
European 
Society of 
Gastrointest
inal 
Endoscopy 
(ESGE) 
2013 Low risk group (patients with 1–2 tubular 
adenomas<10mm with low grade dysplasia), 
Participation in existing 
National screening 
programmes 10 years after the 
index colonoscopy. 
100 
High-risk group (patients with adenomas with 
villous histology or high grade dysplasia or 
≥10mm in size, or ≥3 adenomas) 
Colonoscopy 3 years after the 
index colonoscopy  
Australia 2011 Low risk adenomas (patients with one or two 
small (<10 mm) tubular adenomas). 
Colonoscopy at 5 years 
 
101 
High-risk adenomas (three or more 
adenomas, ≥10mm, or with tubulovillous, or 
villous histology, or high grade dysplasia) 
Colonoscopy at 3 years 
 
Multiple (Five or more) adenomas Follow up at 12 months  
Possible incomplete excision adenoma  Colonoscopy 3-6 months 
Japan 2015 Uncategorized -  
Comments: 
Management of diminutive adenoma (<5 mm) 
has not been established.  In brief, there is no 
uniform Japanese approach (removal or 
follow-up) for diminutive adenomas, and 
controversy remains.   
‘Follow-up colonoscopy should 
be performed within 3 years 
after polypectomy’ 
102 
EU 2012 Low Risk (1–2 small adenomas) Routine screening 35 
Intermediate Risk (3 or more adenomas or an 
adenoma ≥10 mm) 
3-year interval to the first 
surveillance colonoscopy 
High-risk (5 or more adenomas or an adenoma 
of size 20 mm or larger).   
An additional clearing 
colonoscopy at 12 
months may be warranted  
Cut-off age for stopping surveillance is usually 75 years – does not preclude further 
surveillance for clinical or other reasons. 
Netherlands 2013 Revised guideline 2002 onwards 
recommended, patients with three or more 
patients with fewer than three adenomas 
3 years colonoscopy  45,103  
  
6 years colonoscopy  
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Table 2 – PICOTS Criteria Applied 637 
PICOT 
Category 
Inclusion Exclusion 
Population Patients diagnosed with (resected) colorectal 
adenomatous polyp(s) 
Patients with diagnosed colorectal 
cancer or sessile serrated adenomasa 
Intervention Interventions given for the management of 
colorectal cancer risk associated with the 
presence of a baseline adenoma, i.e.  a follow 
up examination, surveillance test or 
reassessment by an appropriate means 
including colonoscopy and comparators listed 
below; 
 
Interventions not currently in clinical 
use outside of trial for e.g.  novel 
biomarkers 
Comparison Endoscopy, FOBT, FIT or CTC Tests in development / biomarker 
based tests not currently in clinical use 
outside of trial for e.g.  novel 
biomarkers 
Outcome Incidence of adenoma; recurrent 
/metachronous adenoma; colorectal cancer; 
‘positive’ tests (in the case of qualitative 
FOBT, FIT, +/- other investigational tests) 
where a positive results indicates the need for 
further clinical investigation to treat/ resect 
potential lesions detected; Costs, LYG, Quality 
Adjusted Life Years, Disability Adjusted Life 
Years or other unit of health gain. 
 
Time No time limits were imposed 
Study designs Economic evaluations where published as 
academic papers are eligible for inclusion 
Case series, case reports, and reports 
from grey literature and conference 
proceedings; excluded from the review 
owing to the high potential for bias.  
RCTs and controlled trials reported 
effects and other formats than 
controlled trials, cohort studies, case–
control whilst considered within the 
quality evaluation within models are 
not directly included. 
FOBT = faecal occult blood testing, CTC = computed tomographic colonography, RCTs = Randomised 638 
controlled trials  639 
a Sessile serrated lesions are often added to guidelines addressing the umbrella term polyp/ 640 
adenoma, clear pathological and molecular distinctions are now recognised, thus we refer 641 
to comprehensive recent work on this pathology for further clinical - 25,26.   642 
  643 
31 
 
 
 644 
  645 
32 
 
 
References 646 
1.  American Cancer Society. Lifetime Risk of Developing or Dying From Cancer. Am 647 
Cancer Soc. 2015:1-5. 648 
2.  Bonelli L. Epidemiology and screening: what’s new? Color Dis. 2015;17:10-14. 649 
doi:10.1111/codi.12815. 650 
3.  GLOBOCAN. Colorectal Cancer Estimated Incidence, Mortality and Prevalence 651 
Worldwide in 2012. 2012. 2012. 652 
4.  Atkin WS, Valori R, Kuipers EJ, et al. European guidelines for quality assurance in 653 
colorectal cancer screening and diagnosis. First Edition--Colonoscopic surveillance 654 
following adenoma removal. Endoscopy. 2012;44 Suppl 3:SE151-63. doi:10.1055/s-655 
0032-1309821. 656 
5.  Winawer SJ, Zauber AG. Colonoscopic polypectomy and the incidence of colorectal 657 
cancer. Gut. 2001;48(6):753-754. doi:10.1136/gut.48.6.753. 658 
6.  American Cancer Society. What are the survival rates for colorectal cancer by stage? 659 
2015:1-3. 660 
7.  Knudsen AB, Zauber AG, Rutter CM, et al. Estimation of Benefits, Burden, and Harms 661 
of Colorectal Cancer Screening Strategies. Jama. 2016;315(23):2595. 662 
doi:10.1001/jama.2016.6828. 663 
8.  Curry SJ, Byers T, Hewitt M. Fulfilling the Potential for Cancer Prevention and Early 664 
Detection.; 2003. 665 
9.  Facciorusso A, Ferrusquía J, Muscatiello N. Lead time bias in estimating survival 666 
outcomes. Gut. 2016;65(3):538-539. doi:10.1136/gutjnl-2015-310199. 667 
10.  Tang V, Boscardin WJ, Stijacic-Cenzer I, Lee SJ. Time to benefit for colorectal cancer 668 
screening: survival meta-analysis of flexible sigmoidoscopy trials. BMJ. 669 
2015;350(apr16_11):h1662. doi:10.1136/bmj.h1662. 670 
11.  Edwards BK, Ward E, Kohler B a, et al. Annual Report to the Nation on the Status of 671 
Cancer, 1975–2006, Featuring Colorectal Trends and Impact of Interventions (Risk 672 
Factors, Screening, and Treatment) to Reduce Future Rates. Cancer. 2010;116(3):544-673 
573. doi:10.1002/cncr.24760.Annual. 674 
12.  Citarda F, Tomaselli G, Capocaccia R, Barcherini S, Crespi M. Efficacy in standard 675 
clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. 676 
Gut. 2001;48(6):812-815. doi:10.1136/gut.48.6.812. 677 
13.  Winawer SJ, Zauber AG, Ho MN, et al. Prevention of Colorectal Cancer by 678 
colonoscopic polypectomy. N Engl J Med. 1993;329(27):1977-1981. 679 
14.  Ladabaum U, Schoen RE. Post-Polypectomy Surveillance: Looking for the Goldilocks 680 
“Just Right” Zone. Gastroenterology. 2016;(February). 681 
doi:10.1053/j.gastro.2016.01.033. 682 
15.  Coleman HG, Loughrey MB, Murray LJ, et al. Colorectal Cancer Risk Following 683 
Adenoma Removal: A Large Prospective Population-Based Cohort Study. Cancer 684 
Epidemiol Biomarkers Prev. 2015;24(9):1373-1380. doi:10.1158/1055-9965.EPI-15-685 
0085. 686 
16.  Lieberman D. Colon-Polyp Surveillance — Do Patients Benefit? N Engl J Med. 687 
2014;371(9):860-861. doi:10.1056/NEJMe1407152. 688 
17.  Strum WB. Colorectal Adenomas. N Engl J Med. 2016;374(11):1065-1075. 689 
doi:10.1056/NEJMra1513581. 690 
18.  Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-691 
tumor development. N Engl J Med. 1988;319(9):525-532. 692 
33 
 
 
19.  College of American Pathologists. Colon polyps. 2011. 693 
http://www.cap.org/apps/docs/reference/myBiopsy/colon_adenomatous_polyps.pdf694 
. Accessed January 4, 2016. 695 
20.  Stryker SJ, Wolff BG, Culp CE, Libbe SD, Ilstrup DM, MacCarty RL. Natural history of 696 
untreated colonic polyps. Gastroenterology. 1987;93(5):1009-1013. 697 
21.  Rutter CM, Yu O, Miglioretti DL. A hierarchical non-homogenous Poisson model for 698 
meta-analysis of adenoma counts. Stat Med. 2007;26(1):98-109. 699 
doi:10.1002/sim.2460. 700 
22.  Sugumar A, Sinicrope F a. Serrated polyps of the colon. F1000 Med Rep. 701 
2010;2(December):89. doi:10.3410/M2-89. 702 
23.  Lanspa SJ, Lynch HT. Sessile Serrated Adenomas: Why Conventional Endoscopy Is 703 
Okay for Unconventional Polyps. Dig Dis Sci. 2014;59(12):2848-2849. 704 
doi:10.1007/s10620-014-3357-2. 705 
24.  Anderson JC, Butterly LF, Goodrich M, Robinson CM, Weiss JE. Differences in 706 
detection rates of adenomas and serrated polyps in screening versus surveillance 707 
colonoscopies, based on the new hampshire Colonoscopy Registry. Clin Gastroenterol 708 
Hepatol. 2013;11(10):1308-1312. doi:10.1016/j.cgh.2013.04.042. 709 
25.  Crockett SD, Snover DC, Ahnen DJ, Baron J a. Sessile Serrated Adenomas: An 710 
Evidence-Based Guide to Management. Clin Gastroenterol Hepatol. 2014;13(1):11-711 
26.e1. doi:10.1016/j.cgh.2013.10.035. 712 
26.  Bordaçahar B, Barret M, Terris B, et al. Sessile serrated adenoma: From identification 713 
to resection. Dig Liver Dis. 2015;47(2):95-102. doi:10.1016/j.dld.2014.09.006. 714 
27.  O’Brien MJ, Zhao Q, Yang S. Colorectal serrated pathway cancers and precursors. 715 
Histopathology. 2015;66(1):49-65. doi:10.1111/his.12564. 716 
28.  Fairley KJ, Li J, Komar M, Steigerwalt N, Erlich P. Predicting the Risk of Recurrent 717 
Adenoma and Incident Colorectal Cancer Based on Findings of the Baseline 718 
Colonoscopy. Clin Transl Gastroenterol. 2014;5(12):e64. doi:10.1038/ctg.2014.11. 719 
29.  Leslie A, Carey FA, Pratt NR, Steele RJC. The colorectal adenoma-carcinoma sequence. 720 
Br J Surg. 2002;89(7):845-860. 721 
30.  Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR. Guidelines 722 
for Colonoscopy Surveillance After Polypectomy: A Consensus Update by the US 723 
Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012;143(3):844-724 
857. doi:http://dx.doi.org/10.1053/j.gastro.2012.06.001. 725 
31.  Lieberman DA, Williams JL, Holub JL, et al. Colonoscopy utilization and outcomes 726 
2000 to 2011. Gastrointest Endosc. 2014;80(1):133-143.e3. 727 
doi:10.1016/j.gie.2014.01.014. 728 
32.  Brand L, Munding J, Pox CP, et al. {ß}-catenin, Cox-2 and p53 immunostaining in 729 
colorectal adenomas to predict recurrence after endoscopic polypectomy. Int J 730 
Colorectal Dis. 2013;28(8):1091-1098. doi:10.1007/s00384-013-1667-z. 731 
33.  Mehta N, Miller J, Feldman M, et al. Findings on Serial Surveillance Colonoscopy in 732 
Patients with Low-Risk Polyps on Initial Colonoscopy. J Clin Gastroenterol. 733 
2010;44(3):e46–e50. doi:doi:10.1097/MCG.0b013e3181a7ed2a. 734 
34.  Lansdorp-Vogelaar I, Fedewa S, Lin CC, Virgo KS, Jemal A. Utilization of surveillance 735 
after Polypectomy in the Medicare population - A cohort study. PLoS One. 736 
2014;9(11):1-21. doi:10.1371/journal.pone.0110937. 737 
35.  Karsa L von, Patnick J, Segnan N, European Colorectal Cancer Screening Guidelines 738 
Working Group. Quality Assurance in Endoscopy in Colorectal Cancer Screening and 739 
34 
 
 
Diagnosis.; 2012. doi:10.2772/15379. 740 
36.  Lieberman D, Moravec M, Holub J, Michaels L, Eisen G. Polyp size and advanced 741 
histology in patients undergoing colonoscopy screening: Implications for CT 742 
Colonography. Gastroenterology. 2008;135(4):1100-1105. 743 
doi:10.1053/j.gastro.2008.06.083.Polyp. 744 
37.  Welch HG. Finding and redefining disease. Eff Clin Pract. 1999;2(2):96-99. 745 
http://www.ncbi.nlm.nih.gov/pubmed/10538482. Accessed September 16, 2015. 746 
38.  Robertson DJ, Greenberg ER, Beach M, et al. Colorectal cancer in patients under close 747 
colonoscopic surveillance. Gastroenterology. 2005;129(1):34-41. 748 
doi:10.1053/j.gastro.2005.05.012. 749 
39.  Radaelli F. The Resect-and-Discard Strategy for Management of Small and Diminutive 750 
Colonic Polyps. Gastroenterol Hepatol (N Y). 2013;9(5):305-308. 751 
40.  Brenner H, Tao S. Superior diagnostic performance of faecal immunochemical tests 752 
for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood 753 
test among 2235 participants of screening colonoscopy. Eur J Cancer. 754 
2013;49(14):3049-3054. doi:10.1016/j.ejca.2013.04.023. 755 
41.  Vasilyev S, Smirnova E, Popov D, et al. A new-generation fecal immunochemical test 756 
(FIT) is superior to quaiac-based test in detecting colorectal neoplasia among 757 
colonoscopy referral patients. Anticancer Res. 2015;35(5):2873-2880. 758 
42.  Lee JK, Liles EG, Bent S, Theodore R, Corley DA. Accuracy of Fecal Immunochemical 759 
Tests for Colorectal Cancer: Systematic Review and Meta-analysis. Ann Intern Med. 760 
2014;160(3):171. doi:10.7326/M13-1484.Accuracy. 761 
43.  Young GP, Symonds EL, Allison JE, et al. Advances in Fecal Occult Blood Tests: The FIT 762 
Revolution. Dig Dis Sci. 2014;60(3):609-622. doi:10.1007/s10620-014-3445-3. 763 
44.  Bowyer HL, Vart G, Kralj-Hans I, et al. Patient attitudes towards faecal 764 
immunochemical testing for haemoglobin as an alternative to colonoscopic 765 
surveillance of groups at increased risk of colorectal cancer. J Med Screen. 766 
2013;20(3):149-156. doi:10.1177/0969141313503953. 767 
45.  van Heijningen E-MB, Lansdorp-Vogelaar I, Steyerberg EW, et al. Adherence to 768 
surveillance guidelines after removal of colorectal adenomas: a large, community-769 
based study. Gut. 2015;64(10):1584-1592. doi:10.1136/gutjnl-2013-306453. 770 
46.  Centre for Reviews and Dissemination. Systematic Reviews: CRD’s Guidance for 771 
Undertaking Reviews in Health Care. York; 2009. 772 
47.  van Hees F, Zauber AG, Klabunde CN, et al. The appropriateness of more intensive 773 
colonoscopy screening than recommended in medicare beneficiaries: a modeling 774 
study. JAMA Intern Med. 2014;174(10):1568-1576. 775 
doi:10.1001/jamainternmed.2014.3889. 776 
48.  van Hees F, Habbema JDF, Meester RG, et al. Should Colorectal Cancer Screening Be 777 
Considered in Elderly Persons Without Previous Screening ? Ann Intern Med. 778 
2014;160(11):750-759. doi:10.7326/M13-2263. 779 
49.  Løberg M, Kalager M, Holme Ø, Hoff G, Adami H-O, Bretthauer M. Long-Term 780 
Colorectal-Cancer Mortality after Adenoma Removal. N Engl J Med. 2014;371(9):799-781 
807. doi:10.1056/NEJMoa1315870. 782 
50.  Singh H, Xue L, Bernstein CN. Risk of Developing Colorectal Cancer Following a 783 
Negative Colonoscopy. Jama. 2006;295(20):2366-2373. 784 
51.  Hassan C, Gimeno-García  a., Kalager M, et al. Systematic review with meta-analysis: 785 
The incidence of advanced neoplasia after polypectomy in patients with and without 786 
35 
 
 
low-risk adenomas. Aliment Pharmacol Ther. 2014;39(9):905-912. 787 
doi:10.1111/apt.12682. 788 
52.  Shamseer L, Moher D, Clarke M, et al. meta-analysis protocols ( PRISMA-P ) 2015 : 789 
elaboration and explanation. 2015;7647(February 2012):1-25. 790 
doi:10.1136/bmj.g7647. 791 
53.  Moher D, Liberati  a, Tetzlaff J, Altman DG, Grp P. Preferred Reporting Items for 792 
Systematic Reviews and Meta-Analyses: The PRISMA Statement (Reprinted from 793 
Annals of Internal Medicine). Phys Ther. 2009;89(9):873-880. 794 
doi:10.1371/journal.pmed.1000097. 795 
54.  Lund H, Brunnhuber K, Juhl C, et al. Towards evidence based research. BMJ. 796 
2016;355(October):1-5. doi:10.1136/bmj.i5440. 797 
55.  Centre for Reviews and Dissemination. CRD Database. 2015. 798 
http://www.crd.york.ac.uk/CRDWeb/HomePage.asp. Accessed September 16, 2015. 799 
56.  Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic 800 
reviews and meta-analyses of studies that evaluate health care interventions: 801 
explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1-34. 802 
doi:10.1016/j.jclinepi.2009.06.006. 803 
57.  Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation 804 
reporting standards (CHEERS)-explanation and elaboration: A report of the ISPOR 805 
health economic evaluation publication guidelines good reporting practices task 806 
force. Value Heal. 2013;16(2):231-250. doi:10.1016/j.jval.2013.02.002. 807 
58.  Cohen DJ, Reynolds MR. Interpreting the Results of Cost-Effectiveness Studies. J Am 808 
Coll Cardiol. 2008;52(25):2119-2126. doi:10.1016/j.jacc.2008.09.018. 809 
59.  Wilschut JA, Habbema JDF, Van Leerdam ME, et al. Fecal occult blood testing when 810 
colonoscopy capacity is limited. J Natl Cancer Inst. 2011;103(23):1741-1751. 811 
doi:10.1093/jnci/djr385. 812 
60.  Gray AM, Clarke PM, Wolstenholme J, Wordsworth S. Applied Methods of Cost-813 
Effectiveness Analysis in Healthcare. Oxford: Oxford University Press; 2011. 814 
61.  O’Mahony JF, Naber SK, Normand C, Sharp L, O’Leary JJ, De Kok IMCM. Beware of 815 
Kinked Frontiers: A Systematic Review of the Choice of Comparator Strategies in Cost-816 
Effectiveness Analyses of Human Papillomavirus Testing in Cervical Screening. Value 817 
Heal. 2015;18(8):1138-1151. doi:10.1016/j.jval.2015.09.2939. 818 
62.  Saini SD, Schoenfeld P, Vijan S. Surveillance colonoscopy is cost-effective for patients 819 
with adenomas who are at high risk of colorectal cancer. Gastroenterology. 820 
2010;138(7):2292. doi:10.1053/j.gastro.2010.03.004. 821 
63.  Hassan C, Pickhardt PJ, Di Giulio E, Kim DH, Zullo A, Morini S. Cost-effectiveness of 822 
early one-year colonoscopy surveillance after polypectomy. Dis Colon Rectum. 823 
2009;52(5):964-971. doi:10.1007/DCR.0b013e31819f244e. 824 
64.  Shaukat A, Parekh M, Lipscomb J, Ladabaum U. Can calcium chemoprevention of 825 
adenoma recurrence substitute or serve as an adjunct for colonoscopic surveillance? 826 
Int J Technol Assess Health Care. 2009;25(2):222-231. 827 
doi:10.1017/S026646230909028X. 828 
65.  Arguedas MR, Heudebert GR, Wilcox CM, M.R. A, G.R. H, C.M. W. Surveillance 829 
colonoscopy or chemoprevention with COX-2 inhibitors in average-risk post-830 
polypectomy patients: A decision analysis. Aliment Pharmacol Ther. 2001;15(5):631-831 
638. 832 
66.  DuPont AW, Arguedas MR, Wilcox CM, A.W. D, M.R. A, C.M. W. Aspirin 833 
36 
 
 
chemoprevention in patients with increased risk for colorectal cancer: a cost-834 
effectiveness analysis. Aliment Pharmacol Ther. 2007;26(3):431-441. 835 
doi:10.1111/j.1365-2036.2007.03380.x. 836 
67.  Ransohoff DF, Lang CA, Kuo HS, et al. Colonoscopic surveillance after polypectomy: 837 
Considerations of cost effectiveness. Ann Intern Med. 1991;114(3):177-182. 838 
doi:10.7326/0003-4819-114-3-177. 839 
68.  Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why 840 
doesn’t it increase at the rate of inflation? Arch Intern Med. 2003;163(14):1637-1641. 841 
doi:10.1001/archinte.163.14.1637. 842 
69.  Martínez ME, Thompson P, Messer K, et al. One-year risk for advanced colorectal 843 
neoplasia: U.S. Versus U.K. risk-stratification guidelines. Ann Intern Med. 844 
2012;157(12):856-864. doi:10.7326/0003-4819-157-12-201212180-00005. 845 
70.  Bang H, Zhao H. Average cost-effectiveness ratio with censored data. J Biopharm Stat. 846 
2012;22(2):401-415. doi:10.1080/10543406.2010.544437. 847 
71.  de Kok IMCM, Polder JJ, Habbema JDF, et al. The impact of healthcare costs in the last 848 
year of life and in all life years gained on the cost-effectiveness of cancer screening. 849 
Br J Cancer. 2009;100(8):1240-1244. doi:10.1038/sj.bjc.6605018. 850 
72.  Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Habbema JDF, Kuipers EJ. Effect 851 
of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl 852 
Cancer Inst. 2009;101(20):1412-1422. 853 
73.  Ramsey SD, Willke RJ, Glick H, et al. Cost-Effectiveness Analysis Alongside Clinical 854 
Trials II—An ISPOR Good Research Practices Task Force Report. Value Heal. 855 
2015;18(2):161-172. doi:10.1016/j.jval.2015.02.001. 856 
74.  Aranda-Hernández J. Seeing better - Evidence based recommendations on optimizing 857 
colonoscopy adenoma detection rate. World J Gastroenterol. 2016;22(5):1767. 858 
doi:10.3748/wjg.v22.i5.1767. 859 
75.  Leufkens AM, Oijen MGH van, Vleggaar FP, Siersema PD. Factors influencing the miss 860 
rate of polyps in a tandem colonoscopy study. Endoscopy. 2012;44:470-475. 861 
doi:10.1055/s-0031-1291666. 862 
76.  Van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, Van Deventer SJ, Dekker E. Polyp miss 863 
rate determined by tandem colonoscopy: A systematic review. Am J Gastroenterol. 864 
2006;101(2):343-350. doi:10.1111/j.1572-0241.2006.00390.x. 865 
77.  Lohsiriwat V. Colonoscopic perforation: Incidence, risk factors, management and 866 
outcome. World J Gastroenterol. 2010;16(4):425-430. doi:10.3748/wjg.v16.i4.425. 867 
78.  Patel SS, Kilgore ML. Cost Effectiveness of Colorectal Cancer Screening Strategies. 868 
Cancer Control. 2015;22(2):248-258. 869 
http://www.ncbi.nlm.nih.gov/pubmed/26068773. 870 
79.  Heresbach D, Chauvin P, Aurélie Hess-Migliorretti, Riou F, Grolier J, Josselin J-M. Cost-871 
effectiveness of colorectal cancer screening with computed tomography 872 
colonography according to a polyp size threshold for polypectomy. Eur J 873 
Gastroenterol Hepatol. 2010;22(6):716-723. doi:10.1097/MEG.0b013e32832c76f6. 874 
80.  Lansdorp-Vogelaar I, Knudsen AB, Brenner H. Cost-effectiveness of colorectal cancer 875 
screening. Epidemiol Rev. 2011;33(1):88-100. doi:10.1093/epirev/mxr004. 876 
81.  Wong MCS, Ching JYL, Chan VCW, Sung JJY. The comparative cost-effectiveness of 877 
colorectal cancer screening using faecal immunochemical test vs. colonoscopy. Sci 878 
Rep. 2015;5(April):13568. doi:10.1038/srep13568. 879 
82.  Quintero E, Castells A, Bujanda L, et al. Colonoscopy versus fecal immunochemical 880 
37 
 
 
testing in colorectal-cancer screening. N Engl J Med. 2012;366(8):697-706. 881 
83.  Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. 882 
Oxford: Oxford University Press; 2006. 883 
84.  Meester RGS, Doubeni C a., Lansdorp-Vogelaar I, et al. Variation in Adenoma 884 
Detection Rate and the Lifetime Benefits and Cost of Colorectal Cancer Screening. 885 
JAMA. 2015;313(23):2349-2358. doi:10.1001/jama.2015.6251. 886 
85.  Terhaar Sive Droste JS, Oort FA, Van Der Hulst RWM, et al. Higher fecal 887 
immunochemical test cutoff levels: Lower positivity rates but still acceptable 888 
detection rates for early-stage colorectal cancers. Cancer Epidemiol Biomarkers Prev. 889 
2011;20(2):272-280. doi:10.1158/1055-9965.EPI-10-0848. 890 
86.  Atkin W. Faecal immunochemical testing (FIT) for adenomas surveillance / FIT for 891 
follow up study. NIHR Heal Technol Assess Program. 2011;(May). 892 
87.  Allison JE, Fraser CG, Halloran SP, Young GP. Population screening for colorectal 893 
cancer means getting FIT: The past, present, and future of colorectal cancer screening 894 
using the fecal immunochemical test for hemoglobin (FIT). Gut Liver. 2014;8(2):117-895 
130. doi:10.5009/gnl.2014.8.2.117. 896 
88.  Wise J. New bowel cancer screening test is recommended for England. Bmj. 897 
2016;273(January):i273. doi:10.1136/bmj.i273. 898 
89.  UK National Screening Committee. UK NSC bowel cancer recommendation. 899 
2016;(January):1. http://legacy.screening.nhs.uk/bowelcancer. Accessed July 3, 2016. 900 
90.  Moss S, Mathews C. NHS Bowel Cancer Screening Programmes: Evaluation of pilot of 901 
Faecal Immunochemical Test : Final report. 2015;(July). 902 
http://legacy.screening.nhs.uk/bowelcancer. Accessed July 2, 2016. 903 
91.  Quintero E, Carrillo M, Gimeno-García AZ, et al. Equivalency of Fecal Immunochemical 904 
Tests and Colonoscopy in Familial Colorectal Cancer Screening. Gastroenterology. 905 
2014;147(5):1021-1030.e1. doi:10.1053/j.gastro.2014.08.004. 906 
92.  Lane JM, Chow E, Young GP, et al. Interval fecal immunochemical testing in a 907 
colonoscopic surveillance program speeds detection of colorectal neoplasia. 908 
Gastroenterology. 2010;139(6):1918-1926. doi:10.1053/j.gastro.2010.08.005. 909 
93.  Chiu SY-H, Chuang S-L, Chen SL-S, et al. Faecal haemoglobin concentration influences 910 
risk prediction of interval cancers resulting from inadequate colonoscopy quality: 911 
analysis of the Taiwanese Nationwide Colorectal Cancer Screening Program. Gut. 912 
2015:gutjnl-2015-310256. doi:10.1136/gutjnl-2015-310256. 913 
94.  Anderson AS, Craigie AM, Caswell S, et al. The impact of a bodyweight and physical 914 
activity intervention (BeWEL) initiated through a national colorectal cancer screening 915 
programme: randomised controlled trial. BMJ. 2014;348(March):g1823. 916 
doi:10.1136/bmj.g1823. 917 
95.  Pakiz B, Flatt S, Mills KC, Jordan LJ, Carethers JM, Rock CL. Quality of life and diet 918 
intervention in individuals at risk for recurrence of colorectal adenomas. 919 
Psychooncology. 2005;14(2):85-93. doi:10.1002/pon.822. 920 
96.  Chan AT, Ladabaum U. Where Do We Stand with Aspirin for the Prevention of 921 
Colorectal Cancer? the USPSTF Recommendations. Gastroenterology. 2016;150(1):14-922 
18. doi:10.1053/j.gastro.2015.11.018. 923 
97.  Drew DA, Cao Y, Chan AT. Aspirin and colorectal cancer: the promise of precision 924 
chemoprevention. Nat Rev Cancer. 2016;16(3):173-186. doi:10.1038/nrc.2016.4. 925 
98.  National Institute for Clinical Excellence (NICE). Colorectal cancer prevention: 926 
colonoscopic surveillance in adults with ulcerative colitis, Crohn’s disease or 927 
38 
 
 
adenomas. 2011;(March). 928 
https://www.nice.org.uk/guidance/cg118/resources/colonoscopic-surveillance-for-929 
preventing-colorectal-cancer-in-adults-with-ulcerative-colitis-crohns-disease-or-930 
adenomas-35109396155077. Accessed April 4, 2015. 931 
99.  New Zealand Guidelines Group. Guidance on Surveillance for People at Increased Risk 932 
of Colorectal Cancer. Wellington; 2011. 933 
100.  Hassan C, Quintero E, Dumonceau JM, et al. Post-polypectomy colonoscopy 934 
surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. 935 
Endoscopy. 2013. doi:10.1055/s-0033-1344548. 936 
101.  Cancer Council Australia Colonoscopy Surveillance Working Party. Clinical Practice 937 
Guidelines for Surveillance Colonoscopy – in Adenoma Follow-up ; Following Curative 938 
Resection of Colorectal Cancer ; and for Cancer Surveillance in Inflammatory Bowel 939 
Disease.; 2011. 940 
102.  Tanaka S, Saitoh Y, Matsuda T, et al. Evidence-based clinical practice guidelines for 941 
management of colorectal polyps. J Gastroenterol. 2015;50(3):252-260. 942 
doi:10.1007/s00535-014-1021-4. 943 
103.  Dekker E, Leerdam M., Hazewinkel Y, et al. Nederlandse Richtlijn Coloscopie 944 
Surveillance. 2013:1-82. 945 
http://www.mdl.nl/uploads/240/1308/Richtlijn_Coloscopie_Surveillance_definitief_2946 
013.pdf. Accessed July 6, 2016. 947 
 948 
  949 
39 
 
 
Figure 1 - PRISMA Flow Diagram 950 
 951 
 952 
 953 
 954 
 955 
 956 
 957 
 958 
 959 
 960 
 961 
 962 
 963 
 964 
 965 
 966 
 967 
 968 
 969 
 970 
 971 
 972 
El
ig
ib
ili
ty
 
In
clu
de
d 
Sc
re
en
in
g 
Id
en
tif
ica
tio
n 
Full-Text Articles 
Excluded, with Reasons  
n = 25 
Records Excluded  
n = 978 
Duplicates Removed  
n = 264 
Additional Records Identified 
Through Other Sources  
n = 1 
Records Identified Through 
Database Searching  
n = 1,273  
Records Screened (1st and 
2nd Author)  
n = 1,010 
Full-Text Articles 
Assessed for Eligibility (1st 
and 2nd Author) n = 32 
Studies Included in 
Qualitative Synthesis  
n = 7 
